Skip to main content
logo
Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
26.71
-0.24 (-0.89%)
Aug 26, 2026, 4:00 PM EDT - Market closed

Nurix Therapeutics Income Statement

Millions USD. Fiscal year is Dec - Nov.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Revenue
36.7783.9854.5576.9938.6329.75
Revenue Growth
-58.40%53.95%-29.14%99.31%29.84%66.95%
Cost of Revenue
340.93316.9221.63189.15184.5116.43
Gross Profit
-304.17-232.92-167.08-112.16-145.87-86.68
Selling, General & Admin
57.0152.7445.9442.93831.2
Operating Expenses
57.0152.7445.9442.93831.2
Operating Income
-361.18-285.67-213.03-155.06-183.87-117.89
Interest & Investment Income
19.5621.9719.7311.123.510.82
Pretax Income
-341.62-263.7-193.3-143.95-180.36-117.06
Income Tax Expense
-0.270.760.27--0.13
Net Income
-341.35-264.46-193.57-143.95-180.36-117.19
Net Income to Common
-341.35-264.46-193.57-143.95-180.36-117.19
Net Income Growth
------
Shares Outstanding (Basic)
1008767544943
Shares Outstanding (Diluted)
1008767544943
Shares Change
25.67%29.12%23.52%11.79%13.32%173.68%
EPS (Basic)
-3.41-3.05-2.88-2.65-3.71-2.73
EPS (Diluted)
-3.41-3.05-2.88-2.65-3.71-2.73
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Free Cash Flow
-304.53-263.47-181.86-89.77-172.05-90.03
Free Cash Flow Per Share
-3.04-3.04-2.71-1.65-3.54-2.10
Gross Margin
--277.36%--145.69%--291.38%
Operating Margin
-982.37%-340.16%-390.52%-201.41%-476.01%-396.25%
Profit Margin
-928.44%-314.90%-354.85%-186.98%-466.93%-393.93%
Free Cash Flow Margin
-828.28%-313.73%-333.38%-116.60%-445.42%-302.61%
EBITDA
-353.18-277.53-205.01-148.93-179.72-115.9
EBITDA Margin
----193.45%--
D&A For EBITDA
88.148.026.134.151.99
EBIT
-361.18-285.67-213.03-155.06-183.87-117.89
EBIT Margin
----201.41%--
Revenue as Reported
36.7783.9854.5576.9938.63-
SEC Filings: 10-K · 10-Q